Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube Sells 1,372 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube sold 1,372 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $16,710.96. Following the transaction, the chief accounting officer now owns 45,640 shares in the company, valued at approximately $555,895.20. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Intellia Therapeutics Price Performance

NTLA stock traded down $0.33 on Tuesday, reaching $12.47. 2,355,020 shares of the company were exchanged, compared to its average volume of 2,637,028. The firm has a market capitalization of $1.27 billion, a PE ratio of -2.29 and a beta of 1.83. The stock’s fifty day moving average price is $14.01 and its 200 day moving average price is $19.28. Intellia Therapeutics, Inc. has a 12 month low of $11.34 and a 12 month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. During the same period last year, the business earned ($1.38) earnings per share. The firm’s quarterly revenue was down 24.1% compared to the same quarter last year. As a group, research analysts expect that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NTLA. Barclays decreased their target price on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Stifel Nicolaus cut their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. Robert W. Baird decreased their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Finally, The Goldman Sachs Group dropped their price target on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $54.94.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently bought and sold shares of NTLA. EverSource Wealth Advisors LLC increased its stake in Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank acquired a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at $41,000. Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics in the 3rd quarter worth about $54,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after buying an additional 794 shares in the last quarter. Finally, KBC Group NV grew its stake in Intellia Therapeutics by 37.3% during the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after buying an additional 1,020 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.